RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Efficacy and Safety of NNC0109-0012 (Anti-IL-20 mAb) in Patients with RA: Results from a Phase 2a Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 9
SP 9
OP 10
DO 10.1177/155989771209006
UL http://mdc.sagepub.com/content/12/9/9.abstract
AB Elevated expression of interleukin-20 (IL-20) and its receptors has been demonstrated in synovium from patients with rheumatoid arthritis (RA) and is thought to be implicated in the pathogenesis of RA. NNC0109-0012 is a novel human monoclonal IgG4 antibody that binds to and neutralizes the activity of IL-20. Results of a Phase 2 study suggest that IL-20 is a potential target for RA therapy.